Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Clin Exp Rheumatol ; 39(5): 961-969, 2021.
Article in English | MEDLINE | ID: mdl-33427620

ABSTRACT

OBJECTIVES: To evaluate the health-related quality of life (HRQoL), disease activity, treatment adherence, and work ability in the real-world setting in patients with axial spondyloarthritis (axSpA). METHODS: QUASAR was a prospective 12-month, observational study involving 23 rheumatology centres across Italy, including adult patients with axSpA according to the Assessment of SpondyloArthritis International Society (ASAS) criteria. Patients were followed at baseline, 3, 6, and 12 months for disease activity and health-related QoL (HRQoL), treatment adherence and work ability. Regression analysis was used to assess the association between treatment and outcome variables. RESULTS: 413 (80.7%) out of axSpA 512 patients were diagnosed with ankylosing spondylitis (AS) and 99 (19.3%) with non-radiographic axSpA (nr-axSpA). Nr-axSpA and AS patients had similar baseline disease activity and HRQoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) were the most frequent medication (n=426, 83.2%). Over the 1-year follow-up, disease activity measures (joint pain and swelling, CRP, global assessment, BASDAI, ASDAS), HRQoL and work ability significantly improved, while few differences emerged between nr-axSpA and AS patients. Treatment satisfaction and adherence questionnaires improved over the 12 months. Patients treated with bDMARDs showed improved outcomes for disease activity measures and HRQoL variables, greater benefit observed in patients with AS. CONCLUSIONS: We found clinical and HRQoL improvement over 1 year in a large, real-world population of nr-axSpA and AS patients treated with bDMARDs or conventional synthetic DMARDs.


Subject(s)
Antirheumatic Agents , Spondylarthritis , Spondylitis, Ankylosing , Adult , Antirheumatic Agents/therapeutic use , Humans , Prospective Studies , Quality of Life , Spondylarthritis/diagnosis , Spondylarthritis/drug therapy , Spondylitis, Ankylosing/diagnosis , Spondylitis, Ankylosing/drug therapy
2.
Bone ; 134: 115297, 2020 05.
Article in English | MEDLINE | ID: mdl-32092480

ABSTRACT

PURPOSE: To investigate the effectiveness of the T-score values provided by Radiofrequency Echographic Multi Spectrometry (REMS) in the identification of patients at risk for incident osteoporotic fractures. METHODS: A population of Caucasian women (30-90 years), enrolled from 2013 to 2016, underwent dual X-ray absorptiometry (DXA) and REMS scans at axial sites. The incidence of fragility fractures was assessed during a follow-up period up to 5 years. Afterwards, patients with and without incident fractures were stratified in two age-matched groups with a 1: 2 proportion (Group F' and Group NF', respectively). The performance of REMS T-score in discriminating between the two groups was quantitatively assessed and compared with DXA. RESULTS: 1516 patients were enrolled and 1370 completed the follow-up (mean ± SD: 3.7 ± 0.8 years; range: 1.9-5.0 years). Fracture incidence was 14.0%. Age-matched groups included 175 fractured patients and 350 non-fractured ones, respectively (median age 70.2 [interquartile range: 61.0-73.3] and 67.3 [65.4-69.8] years, p-value ns). The groups resulted also balanced for height, weight and BMI (p-values ns). As expected, the differences in REMS T-score (for vertebral site, -2.9 [-3.6 to -1.9] in Group F', -2.2 [-2.9 to -1.2] in Group NF') and DXA T-score (-2.8 [-3.3 to -1.9] in Group F', -2.2 [-2.9 to -1.4] in Group NF') were statistically significant (p-value <0.001). Analogous results were obtained for femoral neck. Considering the T-score cut-off of -2.5, REMS identified Group F' patients with a sensitivity of 65.1% and specificity of 57.7% of (OR = 2.6, 95%CI: 1.77-3.76, p < 0.001), whereas DXA showed a sensitivity of 57.1% and a specificity of 56.3% (OR = 1.7, 95%CI: 1.20-2.51, p-value = 0.0032). For femoral neck, REMS sensitivity and specificity were 40.2% and 79.9%, respectively, with an OR of 2.81 (95%CI: 1.80-4.39, p < 0.001). DXA, instead, showed a sensitivity and specificity of 42.3% and 79.3%, respectively, with an OR of 2.68 (95%CI: 1.71-4.21, p < 0.001). CONCLUSIONS: REMS T-score resulted an effective predictor for the risk of incident fragility fractures in a population-based sample of female subjects, representing a promising parameter to enhance osteoporosis diagnosis in the clinical routine.


Subject(s)
Bone Density , Osteoporotic Fractures , Absorptiometry, Photon , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Middle Aged , Osteoporotic Fractures/diagnostic imaging , Osteoporotic Fractures/epidemiology , Spectrum Analysis , Ultrasonography
3.
Clin Exp Rheumatol ; 37(5): 748-755, 2019.
Article in English | MEDLINE | ID: mdl-30943145

ABSTRACT

OBJECTIVES: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting. METHODS: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA. RESULTS: Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup. CONCLUSIONS: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.


Subject(s)
Antirheumatic Agents , Quality of Life , Spondylarthritis , Spondylitis, Ankylosing , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antirheumatic Agents/therapeutic use , Female , Humans , Male , Middle Aged , Prospective Studies , Spondylarthritis/physiopathology , Spondylarthritis/psychology , Spondylitis, Ankylosing/physiopathology , Spondylitis, Ankylosing/psychology , Young Adult
4.
Clin Drug Investig ; 39(6): 565-575, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30941736

ABSTRACT

BACKGROUND: Identification of predictors of clinical response to certolizumab-pegol (certolizumab) may aid the decision-making process for treating patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA). OBJECTIVE: The aim of our study was to evaluate the effectiveness of certolizumab and identify any predictors of favorable outcome in patients with RA, PsA, or SpA. METHODS: We studied 355 RA, SpA, and PsA patients starting treatment with certolizumab. Endpoints of the study were drug survival and identification of predictors of clinical outcome. Drug retention was analyzed via the Kaplan-Meier method, and hazard ratios (HRs) were estimated using Cox regression models. RESULTS: Of 355 certolizumab initiators, 178 had RA, 94 had PsA, and 83 had SpA. Biologic-naïve RA patients had significantly higher survival rates (73.3%) than switchers taking certolizumab as a second-line (49.0%) or third- or next-line biologic agent (51.2%; p = 0.0001). Instead, PsA and SpA patients showed similar drug retention rates regardless of the line of treatment. A significant clinical improvement from baseline was seen at 3 months for RA (28 joint-Disease Activity Score [DAS28]; p = 0.001), PsA (Disease Activity Index for PsA [DAPSA]; p = 0.001), and SpA (Bath Ankylosing Disease Index; p = 0.01). Biologic-naïve patients had the lowest HR (0.31; p = 0.001) of discontinuing certolizumab for RA, and the highest HR (7.94; p = 0.01) of achieving minimal disease activity (MDA) for PsA. For PsA, a predictor of late MDA was the achievement of low/remission DAPSA at 3 months, and 3-month low/remission DAS28 predicted late remission for RA. CONCLUSIONS: Our study revealed that the best predictor of certolizumab effectiveness in unselected patients with RA, PsA, or SpA was a biologic-naïve status and achievement of an early response within 3 months.


Subject(s)
Arthritis, Psoriatic/drug therapy , Arthritis, Rheumatoid/drug therapy , Certolizumab Pegol/therapeutic use , Spondylarthritis/drug therapy , Adult , Female , Humans , Male , Middle Aged , Proportional Hazards Models , Registries , Retrospective Studies , Treatment Outcome
6.
Clin Rheumatol ; 37(3): 667-675, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29411182

ABSTRACT

This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life. PsA patients starting ustekinumab were enrolled from 2014 to 2016. Joint involvement, peripheral or axial, Psoriatic Area Severity Index, Disease Activity Psoriatic Arthritis (DAPSA), Lee Enthesitis Index, Health Assessment Questionnaire, body mass index, comorbidities, co-therapies, mechanism of action, and causes of discontinuation of prior TNFi were collected at baseline, and 6 and 12 months. Twelve-month drug survival was evaluated by Kaplan-Meier curves. Hazard ratios (HRs) of drug discontinuation adjusted for baseline factors were estimated by multiple Cox regression analysis. Percentages of DAPSA-based remission, as crude value and adjusted for drug retention (LUNDEX index), were compared by χ2 test. Mean differences of DAPSA from baseline to 6 and 12 months were compared between naïve and TNF-IR patients by ANOVA. Of 160 PsA patients starting ustekinumab, 54 were naïve and 106 were TNF-IR. Twelve-month drug survival was significantly higher in naïve (87%) than in TNF-IR (68%, p = 0.01). Baseline co-therapy with methotrexate did not increase the persistence on ustekinumab. Naïve patients had the lowest risk of ustekinumab discontinuation (HR 0.27, p = 0.01), and the highest DAPSA-based remission (34%, LUNDEX 26%). Mean differences from baseline of DAPSA was significantly greater in naïve than in TNF-IR patients at 12 months (- 14.4 ± 10 vs. - 4.1 ± 17, p = 0.01). Our data showed that ustekinumab has a good effectiveness in real life and the best outcomes are achieved in biologic-naïve PsA patients.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Ustekinumab/therapeutic use , Adult , Aged , Arthritis, Psoriatic/diagnosis , Female , Humans , Male , Middle Aged , Registries , Severity of Illness Index , Treatment Outcome
7.
J Cardiovasc Med (Hagerstown) ; 19(3): 105-112, 2018 03.
Article in English | MEDLINE | ID: mdl-29283915

ABSTRACT

PURPOSE: Modern cardiac implantable devices provide diagnostic information on several physiological variables which are associated with worsening heart failure, creating an opportunity for early intervention to prevent heart failure symptoms and hospitalizations. We evaluated diagnostic accuracy and workload of a remote monitoring (RM) workflow algorithm which leverages intrathoracic impedance and other device diagnostics. METHODS: In our RM workflow a team of expert nurses was responsible for continuity of care, direct relationship with patients and implementation of a specific protocol to evaluate RM alerts and to limit unnecessary resource consumption. Each patient was univocally assigned to a reference nurse. End points were diagnostic accuracy, healthcare utilization, defined as any hospital admission, and actionability of alerts, defined as medication change or other clinical action. RESULTS: One-hundred twenty-six consecutive patients with implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator were followed for a median time of 23 months. Out of 2176 remote transmissions, 893 (41%) in 111 patients (88.1%) showed clinically relevant events triggered by 574 alerts [2.2 (95% confidence interval = 2.0-2.4) per patient per year]. Among 309 alerts with intrathoracic impedance crossing, heart failure deterioration was confirmed in 116 (37.5%). Clinical actions followed 76/116 (65.5%) true heart failure alerts and 17/193 (8.8%) false-positive alerts (P < 0.001). In particular, drug therapy change followed 72/116 (62.1%) true heart failure alerts and 15/193 (7.8%) false-positive alerts (P < 0.001). Healthcare utilization occurred in 65.5% true heart failure alerts and in 24.9% false-positive alerts (P < 0.001). CONCLUSION: A dedicated workflow algorithm results in more focused clinical surveillance leading to prompt detection and treatment of acute heart failure events without wasting healthcare resource.


Subject(s)
Cardiography, Impedance/instrumentation , Defibrillators, Implantable , Heart Failure/therapy , Remote Sensing Technology , Aged , Aged, 80 and over , Algorithms , Cardiac Resynchronization Therapy/methods , Cardiac Resynchronization Therapy/statistics & numerical data , Cardiac Resynchronization Therapy Devices , Female , Humans , Male , Middle Aged , Monitoring, Ambulatory , Multivariate Analysis , Patient Compliance , Prospective Studies , Workflow
8.
Semin Arthritis Rheum ; 47(1): 108-114, 2017 08.
Article in English | MEDLINE | ID: mdl-28216195

ABSTRACT

OBJECTIVES: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Drug retention was analyzed using Kaplan-Meier and Cox models. Hazard ratios (HR) of golimumab discontinuation were estimated by Cox-regression hazard models. RESULTS: Of 416 patients starting golimumab, 171 biologic-naïve and 245 inadequate responders to prior biologic drugs, 88 had RA, 147 SpA, and 181 PsA. Global 2 years drug retention was 70.2%, with no different hazard of discontinuation among diseases or line of biologic treatment. The strongest predictor of golimumab discontinuation was female gender (HR = 1.95). Golimumab monotherapy was associated with higher risk drug interruption (HR = 1.67). Within SpA, predictors of golimumab discontinuation were female sex (HR = 4.19), and absence of extra-articular manifestations (HR = 4.60). In PsA, duration of disease was negatively associated to drug interruption (HR = 0.93), whereas golimumab monotherapy was positively (HR = 2.21) associated. Interestingly, failing to achieve a good EULAR response at 3 months was the only predictor of golimumab discontinuation for RA patients (HR = 3.03). CONCLUSIONS: This study provided evidence that golimumab has high retention rate in real-life settings. SpA male patients with extra-articular manifestations, PsA patients on co-therapy with DMARDs, and RA patients attaining an early clinical response had the highest probability to continue golimumab over 2 years.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Arthritis, Psoriatic/drug therapy , Arthritis, Rheumatoid/drug therapy , Immunologic Factors/therapeutic use , Spondylarthritis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Aged , Humans , Kaplan-Meier Estimate , Longitudinal Studies , Middle Aged , Proportional Hazards Models , Prospective Studies , Risk Factors , Sex Factors , Time Factors , Treatment Outcome
9.
Ultrasound Med Biol ; 42(6): 1337-56, 2016 06.
Article in English | MEDLINE | ID: mdl-27033331

ABSTRACT

The aim of this paper was to investigate the clinical feasibility and the accuracy in femoral neck densitometry of the Osteoporosis Score (O.S.), an ultrasound (US) parameter for osteoporosis diagnosis that has been recently introduced for lumbar spine applications. A total of 377 female patients (aged 61-70 y) underwent both a femoral dual X-ray absorptiometry (DXA) and an echographic scan of the proximal femur. Recruited patients were sub-divided into a reference database used for ultrasound spectral model construction and a study population for repeatability assessments and accuracy evaluations. Echographic images and radiofrequency signals were analyzed through a fully automatic algorithm that performed a series of combined spectral and statistical analyses, providing as a final output the O.S. value of the femoral neck. Assuming DXA as a gold standard reference, the accuracy of O.S.-based diagnoses resulted 94.7%, with k = 0.898 (p < 0.0001). Significant correlations were also found between O.S.-estimated bone mineral density and corresponding DXA values, with r(2) up to 0.79 and root mean square error = 5.9-7.4%. The reported accuracy levels, combined with the proven ease of use and very good measurement repeatability, provide the adopted method with a potential for clinical routine application in osteoporosis diagnosis.


Subject(s)
Femur Neck/diagnostic imaging , Osteoporosis/diagnostic imaging , Ultrasonography/methods , Absorptiometry, Photon/methods , Aged , Bone Density , Densitometry/methods , Evaluation Studies as Topic , Feasibility Studies , Female , Humans , Middle Aged , Reproducibility of Results
10.
Rheumatol Int ; 35(11): 1943-7, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26048626

ABSTRACT

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominantly inherited autoinflammatory disease caused by mutations in the TNFRSF1A gene. Treatment is aimed at preventing acute disease attacks, improving quality of life, and preventing long-term complications such as systemic reactive amyloidosis. Biologic agents have significantly improved TRAPS management. In particular, interleukin 1 (IL-1) inhibition either with the recombinant IL-1 receptor antagonist anakinra or with the human IgG1 anti-IL-1ß monoclonal antibody canakinumab has recently shown to induce a prompt and stable disease remission. Conversely, the successful experience with IL-6 inhibition is nowadays limited to a single patient. Anyway, introduction of new treatment options for patients requiring a lifelong therapy is desirable. We describe two TRAPS patients (son and father) successfully treated with canakinumab and tocilizumab, respectively. In particular, we highlight the clinical and laboratory efficacy as well as the good safety profile of tocilizumab during a 42-month follow-up period.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal/administration & dosage , Fever/drug therapy , Hereditary Autoinflammatory Diseases/drug therapy , Immunosuppressive Agents/administration & dosage , Adult , Child, Preschool , DNA Mutational Analysis , Drug Administration Schedule , Fever/diagnosis , Fever/genetics , Fever/immunology , Genetic Predisposition to Disease , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/genetics , Hereditary Autoinflammatory Diseases/immunology , Humans , Male , Mutation , Phenotype , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type I/immunology , Time Factors , Treatment Outcome
11.
Heart Rhythm ; 12(2): 330-7, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25444853

ABSTRACT

BACKGROUND: Energy demand of remote monitoring in cardiac implantable electronic devices has never been investigated. Biotronik Home Monitoring (HM) is characterized by daily transmissions that may affect longevity. OBJECTIVE: The aim of the study was to retrospectively compare longevity of a specific dual-chamber pacemaker model in patients with HM on and patients with HM off. METHODS: Hospital files of 201 patients (mean age 87 ± 10 years, 78 men) who had received a Biotronik Cylos DR-T pacemaker between April 2006 and May 2010 for standard indication were reviewed. In 134 patients (67%), HM was activated. The primary end point was device replacement due to battery depletion. RESULTS: The median follow-up period was 56.4 months (interquartile range 41.8-65.2 months). The estimated device longevity was 71.1 months (95% confidence interval [CI] 69.1-72.3 months) in the HM-on group and 60.4 months (CI 55.9-65.1 months) in the HM-off group (P < .0001). The frequency of inhospital visits with significant device reprogramming was higher in the HM-on group than in the HM-off group (33.3% vs 25.0%, respectively; P = .03). Lower ventricular pulse amplitude (2.3 ± 0.4 V vs 2.7 ± 0.5 V; P < .0001) and pacing percentage (49% ± 38% vs 64% ± 38%; P = .02), both calculated as time-weighted averages, were observed with HM on as compared with HM off. Patient attrition was significantly lower in the HM-on group (9.7%; 95% CI 3.0%-28.7%) than in the HM-off group (45.6%; 95% CI 30.3%-64.3%) (P < .0001). CONCLUSION: In normal practice, energy demand of HM, if present, was overshadowed by programming optimization likely favored by continuous monitoring. Pacemakers controlled remotely with HM showed an 11-month longer longevity. Patient retention was superior.


Subject(s)
Arrhythmias, Cardiac/physiopathology , Heart Rate/physiology , Monitoring, Physiologic/methods , Pacemaker, Artificial , Telemetry/methods , Aged , Aged, 80 and over , Equipment Design , Female , Follow-Up Studies , Humans , Male , Reproducibility of Results , Retrospective Studies , Time Factors
12.
Ultrasound Med Biol ; 41(1): 281-300, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25438845

ABSTRACT

We investigated the possible clinical feasibility and accuracy of an innovative ultrasound (US) method for diagnosis of osteoporosis of the spine. A total of 342 female patients (aged 51-60 y) underwent spinal dual X-ray absorptiometry and abdominal echographic scanning of the lumbar spine. Recruited patients were subdivided into a reference database used for US spectral model construction and a study population for repeatability and accuracy evaluation. US images and radiofrequency signals were analyzed via a new fully automatic algorithm that performed a series of spectral and statistical analyses, providing a novel diagnostic parameter called the osteoporosis score (O.S.). If dual X-ray absorptiometry is assumed to be the gold standard reference, the accuracy of O.S.-based diagnoses was 91.1%, with k = 0.859 (p < 0.0001). Significant correlations were also found between O.S.-estimated bone mineral densities and corresponding dual X-ray absorptiometry values, with r(2) values up to 0.73 and a root mean square error of 6.3%-9.3%. The results obtained suggest that the proposed method has the potential for future routine application in US-based diagnosis of osteoporosis.


Subject(s)
Bone Density , Densitometry/methods , Osteoporosis/diagnostic imaging , Osteoporosis/physiopathology , Spinal Diseases/diagnostic imaging , Spinal Diseases/physiopathology , Ultrasonography/methods , Feasibility Studies , Female , Humans , Image Interpretation, Computer-Assisted/methods , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
13.
J Interv Card Electrophysiol ; 41(3): 203-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25256800

ABSTRACT

INTRODUCTION: Remote monitoring (RM) is becoming the new standard for follow-up of patients with cardiac implantable electronic devices. The aim of the present study was to evaluate patients' acceptance and satisfaction of RM by using a specific designed questionnaire. METHODS: The questionnaire is composed of 12 items aimed at analyzing 5 aspects of patient's acceptance and satisfaction of RM, with a scale ranging from 0 (the worst) to 4 (the best). The questionnaire was submitted to 163 ICD patients (147 male, 71 ± 12 years, 39 CRT-D), and followed by the CareLink Network Medtronic system, after a median follow-up of 20 months (13-26 months). Cronbach's alpha for reliability of the administered questionnaire was 0.73. RESULTS: The mean score of all 12 items was 3.5 ± 0.3; in detail: (i) relationship with healthcare provider 3.3 ± 0.7; (ii) ease of use of network technology 3.5 ± 0.5; (iii) related psychological aspects 3.5 ± 0.4; (iv) implication of general health 3.4 ± 0.6; (v) overall satisfaction 3.8 ± 0.3. CareLink naïve patients had better scores than those with previous in-person follow-up experience (3.6 ± 0.6 vs. 3.4 ± 0.7, p = 0.027), while no differences were observed between wireless and inductive systems, neither considering the living distance from the hospital. The main independent predictor of patient satisfaction was the implantation of CRT-D [Exp(beta) = 6.80 (1.34-34.62)] (p = 0.021). No correlation was found between age and ease of use of RM, while a positive correlation was observed between age and benefits on psychological aspects (p < 0.01). CONCLUSIONS: ICD patients showed a high level of acceptance and satisfaction for RM. Patients with CRT-D perceived the greatest benefit.


Subject(s)
Defibrillators, Implantable/psychology , Defibrillators, Implantable/statistics & numerical data , Heart Failure/prevention & control , Patient Acceptance of Health Care/psychology , Patient Acceptance of Health Care/statistics & numerical data , Telemedicine/statistics & numerical data , Activities of Daily Living/psychology , Age Distribution , Aged , Female , Follow-Up Studies , Heart Failure/epidemiology , Heart Failure/psychology , Humans , Italy/epidemiology , Longitudinal Studies , Male , Prevalence , Reproducibility of Results , Sensitivity and Specificity , Surveys and Questionnaires , Treatment Outcome
14.
Acta Biomed ; 84(1): 23-9, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-24189759

ABSTRACT

BACKGROUND AND AIMS: Oral bisphosphonates have been used successfully in patients with rheumatoid arthritis (RA), but their use for the treatment of corticosteroid induced osteoporosis may be limited by poor compliance. Neridronate, an intramuscular and intravenous aminobisphosphonate approved for the treatment of osteogenesis imperfecta and Paget's disease, is also effective in postmenopausal osteoporosis. The aim of this study was to compare the adherence of intramuscular neridronate versus oral alendronate or risedronate in patients with RA with corticosteroid-induced osteopenia. METHODS: This randomised, open label, parallel-group, single centre study enrolled post-menopausal women (50-70 years), with RA and osteopenia (T-score >-2.5) who were receiving stable dose of methylprednisolone 5 mg or equivalent within the previous 3 months, and expected to continue therapy for at least 12 months. Patients were treated with intramuscular neridronate 25 mg administered once a month, or oral alendronate 70 mg or oral risedronate 35 mg both administered once-weekly, for 12 months. The main outcome measure was adherence to treatment over 1 year, assessed using the Morisky Medication Adherence Scale 4-item (MMAS-4; adherence defined as patients with MMAS-4 score ≥3). RESULTS: Of 87 women (mean age 61.5 ± 9.2 years) enrolled, 30 were randomized to neridronate, 27 to alendronate and 30 to risedronate therapy. Adherence rates after 12 months were significantly higher with neridronate than with alendronate or risedronate (76.7% vs 47.8% and 48.0%; p<0.05 for both versus neridronate). After 12 months, lumbar and femoral neck BMD and DAS28 were significantly improved in all groups compared with baseline (p<0.05) with no significant difference between the three treatment groups. CONCLUSION: Neridronate is associated with significantly improved adherence to therapy compared with alendronate and risedronate, and improves BMD and disease activity in postmenopausal women with RA and osteopenia. Intramuscular monthly neridronate represents a convenient treatment option for patients with RA using corticosteroids.


Subject(s)
Bone Density , Diphosphonates , Adrenal Cortex Hormones , Alendronate , Arthritis, Rheumatoid , Bone Density/drug effects , Humans , Treatment Outcome
15.
Clin Cases Miner Bone Metab ; 9(1): 50-5, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22783337

ABSTRACT

Studies of the mechanisms of periprosthetic bone loss have led to the development of pharmacologic strategies intended to enhance bone mass recovery after surgery and consequently prevent aseptic loosening and prolong the implant survival. Bisphosphonates, potent anti-resorptive drugs widely used in the treatment of osteoporosis and other disorders of bone metabolism, were shown to be particularly effective in reducing periprosthetic bone resorption in the first year after hip and knee arthroplasty, both cemented and cementless. Based on these results, we investigated the inhibitory effects of ibandronate on periprosthetic bone loss in a 2-year study of postmenopausal women that underwent cementless total hip arthroplasty. In the first 6 months both groups (A, treated with ibandronate 3 mg i.v. within five days after surgery and then with oral ibandronate 150 mg/month, plus calcium and vitamin D supplementation; and B, treated with calcium and vitamin D supplementation only) experienced bone loss, though to a lesser extent in group A. After 12 months, group A showed a remarkable BMD recovery, that was statistically significant versus baseline values (about +1, 74% of global BMD) and most evident in region R1 (+3, 81%) and R2 (+4, 12%); in group B, on the contrary, BMD values were unchanged compared with those at 6 months post-surgery. Quality of life scores also showed a greater improvement in group A, both at 6 and 12 months after surgery, likely because of the pain-reducing effects of ibandronate treatment.

16.
J Interv Card Electrophysiol ; 33(1): 113-21, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21882010

ABSTRACT

BACKGROUND: In 2007, great concern arose regarding failure of implantable cardioverter defibrillator (ICD) leads from several manufacturers. OBJECTIVE: Of this analysis was to evaluate the incidence and predictors of Sprint Fidelis lead failure in order to find the best clinical strategy to prevent lead-related adverse events. METHODS: Four hundred fourteen patients (357 male, 67 ± 12 years) with ICD equipped with right ventricular Sprint Fidelis leads were followed up in our institution. RESULTS: Over a median follow-up of 35 months (25th-75th percentile = 27-47 months) and a total follow-up of 1,231 patient-years, lead failures occurred in 40 of 414 (9.7%) patients. The annual rate was 3.2% per patient-year. Thirty-five (87.5%) failures were caused by pacing-sensing connector fracture. The risk of lead fracture was higher in patients younger than 70 years (odds ratio = 2.31; 95% confidence interval = 1.14-4.68, p = 0.02). Among 30 patients with pacing-sensing conductor failure and available device diagnostics for failure alerting, the diagnostic parameter which first responded to lead failure was the sensing integrity counter in 15 of 30 (50%), pacing impedance in 12 of 30 (40%), and non-sustained ventricular tachycardia in 3 of 30 (10%). The median time (25th-75th percentile) between diagnostics alert and lead failure-related adverse events or failure acknowledgment was 2.2 (0.3-13.0) days. Twenty-two patients suffered inappropriate shocks due to lead failure. In 50% of patients, daily monitoring by device diagnostics would have alerted physicians to impending lead failure at least 1 day in advance. CONCLUSIONS: Automatic algorithms based on device diagnostics may detect impending lead failure in nearly 50% of cases. Remote monitoring may prevent failure-related adverse events.


Subject(s)
Defibrillators, Implantable/adverse effects , Aged , Equipment Failure , Female , Humans , Male , Middle Aged , Risk Factors , Survival Analysis
17.
Drug Des Devel Ther ; 5: 445-54, 2011.
Article in English | MEDLINE | ID: mdl-22087064

ABSTRACT

Bisphosphonates have a long history in the treatment of osteoporosis and bone-related disease. This review focuses on the use of a specific nonaminobisphosphonate, clodronate, which appears to be much better tolerated than other bisphosphonates and free of high-risk contraindications. Specifically, this paper reviews its use in the prevention of osteoporosis in postmenopausal women, taking into account its tolerability profile and recent safety issues arising regarding the use of bisphosphonates.


Subject(s)
Clodronic Acid/adverse effects , Clodronic Acid/therapeutic use , Diphosphonates/adverse effects , Osteoporosis/drug therapy , Osteoporosis/prevention & control , Clodronic Acid/economics , Clodronic Acid/pharmacokinetics , Clodronic Acid/pharmacology , Diphosphonates/administration & dosage , Diphosphonates/pharmacokinetics , Diphosphonates/therapeutic use , Female , Humans , Male , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/prevention & control
18.
Clin Cases Miner Bone Metab ; 8(1): 55-6, 2011 Jan.
Article in English | MEDLINE | ID: mdl-22461804

ABSTRACT

A prosthetic implant modifies the physiological transmission of loads to the bone, initiating a remodeling process.Studies of the mechanisms responsible for periprosthetic bone loss contributed to the definition of new pharmacological strategies that may prevent aseptic implant loosening. Bisphosphonates are a class of drugs useful to this purpose, and have been shown to be effective in reducing periprosthetic resorption during the first year after the implant. We aimed to assess the inhibitory effect on periprosthetic osteolysis of ibandronate, a highly potent aminobisphosphonate, administered orally and IV with an extended interval between doses and optimal treatment adherence. In view of the fact that periprosthetic remodeling takes place during the first 6-12 months after surgery and is ultimately responsible for prosthesis longevity, we may conclude that the administration of high dosage ibandronate postsurgery by IV bolus and subsequently as cyclic oral treatment reduced cortical osteopenia in the metaphyseal region, and in the calcar region of the proximal femur. This therapy might therefore be used as preventive measure against postsurgical osteopenia and probably also against aseptic loosening.

19.
Europace ; 12(5): 674-9, 2010 May.
Article in English | MEDLINE | ID: mdl-20200019

ABSTRACT

AIMS: To evaluate patients' acceptance and satisfaction of the Home Monitoring (HM) remote control system after 1 year of follow-up by a self-made questionnaire (HM Acceptance and Satisfaction Questionnaire, HoMASQ) specifically designed for this purpose. METHODS AND RESULTS: The HoMASQ contains 12 items designed to investigate five different aspects strictly connected to patient's acceptance and satisfaction of remote monitoring: (i) relationship with their healthcare provider, (ii) easy of use of HM technology, (iii) related psychological aspects, (iv) implications on general health, and (v) overall satisfaction. Each item was rated on a five-point scale: from 0 to 4 with favourable responses score > or =2. The theoretical maximum total score (the highest detected acceptance and satisfaction level) was 48. The HoMASQ was given to 119 patients followed by HM during the 1-year follow-up visit. Ninety-nine percent of all the administered questionnaire items were answered. The mean total score was 40.8 +/- 5.4 with a mean percentage of favourable answers of 96.3 +/- 18.8% (CI 95.2 - 97.2%). The mean scores for each of the five areas of the HoMASQ were: 3.0 +/- 0.9 for relationship, 3.4 +/- 0.6 for easy of use, 3.4 +/- 0.9 for psychological aspects, and 3.4 +/- 0.8 for clinical implication and overall satisfaction. Cronbach's alpha for reliability of the HoMASQ was 0.73. CONCLUSION: A high level of acceptance and satisfaction after 1-year remote control by HM was detected by the five-point scale HoMASQ, which showed a good internal reliability.


Subject(s)
Arrhythmias, Cardiac/therapy , Defibrillators, Implantable , Electrocardiography, Ambulatory/methods , Patient Acceptance of Health Care , Patient Satisfaction , Surveys and Questionnaires , Aged , Aged, 80 and over , Atrioventricular Block/therapy , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged , Physician-Patient Relations , Quality of Life , Regression Analysis , Reproducibility of Results , Sick Sinus Syndrome/therapy , Syncope, Vasovagal/therapy
20.
Ann N Y Acad Sci ; 1117: 159-64, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17646267

ABSTRACT

Aggressive bone resorption is well recognized in psoriatic arthritis (PsA). By using in vitro osteoclastogenesis models, consisting of unstimulated mononuclear cells from peripheral blood (PBMCs) and synovial fluid (SFMCs) of PsA patients, we demonstrated the spontaneous OC formation in both culture systems. In PBMCs the osteoclastogenesis was T cell-dependent while it was T cell- and fibroblast-dependent in SFMCs. T cells isolated from PBMCs and SFMCs of PsA patients overexpressed RANKL and TNF-alpha, and fibroblasts from SFMCs overexpressed RANKL. Thus, T cells and fibroblasts from synovial fluid through the production of osteoclastogenic cytokines could support the OC formation in PsA patients.


Subject(s)
Arthritis, Psoriatic/metabolism , Fibroblasts/metabolism , Synovial Fluid/metabolism , Case-Control Studies , Cell Differentiation , Cells, Cultured , Female , Humans , Leukocytes, Mononuclear/metabolism , Male , Models, Biological , Osteoclasts/metabolism , RANK Ligand/metabolism , Synovial Fluid/cytology , T-Lymphocytes/metabolism , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...